Ann Dermatol.  2019 Oct;31(5):585-588. 10.5021/ad.2019.31.5.585.

A Pilot Study about Possible Gluten Sensitivity in Korean Urticaria Patients

• Park J
• Lee D
• Kwon SH
• Song JY
• Baek YS
• Jeon J

• KMID: 2456240
• DOI: http://doi.org/10.5021/ad.2019.31.5.585

Abstract

No abstract available.

MeSH Terms

Glutens*
Humans
Pilot Projects*
Urticaria*
Glutens

Figure

• 

  Fig. 1 First visit questionnaire. Simplified questionnaire usedto collect information regarding concomitant symptoms and to screen for ‘gluten sensitivity possible’ patients.

• 

  Fig. 2 Flowchart of the study intervention and patients disposition. (A) ‘Gluten sensitivity (GS) possible’ patients maintained their initial dose of medication during the first week of the gluten-free diet while waiting for gluten washout. Patients were then instructed to successively reduce their medication use. Patients who experienced symptomatic relief while on the GFD were labeled as ‘GS suspected’ and were asked to complete a gluten challenge for three days. ‘GS suspected’ patients who developed urticarial symptoms during the challenge were defined as ‘GS confirmed’. (B) Values are presented as the number of patients. Among the 60 screened patients, 40 (‘GS possible’, 66%) had gastrointestinal symptoms. Twenty-three patients agreed to follow a GFD, of which 20 (‘GS suspected’, 87%) experienced an improvement in urticaria symptoms during the 4-week GFD trial. A total of 15 patients then completed the gluten challenge, of which 14 developed urticarial symptoms (‘GS confirmed’, 93%) by the second day of the challenge.

Reference

1. Humbert P, Pelletier F, Dreno B, Puzenat E, Aubin F. Gluten intolerance and skin diseases. Eur J Dermatol. 2006; 16:4–11.

2. Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol Hepatol. 2009; 24:1347–1351.

3. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018; 73:1393–1414.

4. Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015; 45:547–565.

5. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007; 357:1731–1743.

6. Anderson RP. Coeliac disease. Aust Fam Physician. 2005; 34:239–242.

7. Di Sabatino A, Volta U, Salvatore C, Biancheri P, Caio G, De Giorgio R, et al. Small amounts of gluten in subjects with suspected nonceliac gluten sensitivity: a randomized, double-blind, placebo-controlled, cross-over trial. Clin Gastroenterol Hepatol. 2015; 13:1604–1612.e3.

8. Bruins MJ. The clinical response to gluten challenge: a review of the literature. Nutrients. 2013; 5:4614–4641.

9. Gwee KA, Ghoshal UC, Chen M. Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management. J Gastroenterol Hepatol. 2018; 33:99–110.

10. Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007; 85:160–166.